

Curriculum Vitae

Personal information **Stefan Verweij**

Work experience

1. Employer: CBG_MEB
 - Start date: 082020
 - End date:
 - Position: Data scientist
 - Activities:
 - Country: Netherlands
2. Employer: Dupont Nutrition & Biosciences
 - Start date: 012020
 - End date: 062020
 - Position: Data scientist
 - Activities: Researching protein engineering
 - Country: Netherlands

Education and training

1. Subject: University of Groningen
 - Start date: 022022
 - End date:
 - Qualification: PhD
 - Organisation: Epidemiology Methodology Real world evidence RWE Biostatistics
 - Country: Netherlands
2. Subject: Wageningen University
 - Start date: 092017
 - End date: 122019
 - Qualification: MSc Bioinformatics
 - Organisation: Bioinformatics Machine Learning Data science _omics Advanced mathematics
 - Country: Netherlands
3. Subject: Wageningen University
 - Start date: 092013
 - End date: 052017
 - Qualification: BSc Biotechnology
 - Organisation: Molecular biology Gene technology Bioprocess engineering _omics
 - Country: Netherlands
4. Subject: Wageningen University
 - Start date: 022016
 - End date: 072016
 - Qualification: Minor Innovation & Entrepreneurship
 - Organisation: Innovation management Niche creation Sustainable entrepreneurship
 - Country: Netherlands

Additional information

Publications

- **Verweij, S.**, Haverhoek, V., Bergman, E., Westman, G., & Bloem, L. T. (2024). A Natural Language Processing Approach towards Harmonized Communication of Uncertainties Identified during the European Medicine Authorization Process. *Clinical Pharmacology & Therapeutics*.
- **Verweij, S.**, Ahmed, W., Zhou, G., Mavridis, D., Nikolakopoulos, S., Elferink, A. J., ... & Hak, E. (2024). Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?. *Pharmacoepidemiology and Drug Safety*, 33(5), e5810.
- van Walstijn, C., **Verweij, S.**, Care, R., Rigsby, P., Clapper, E. B., Markey, K., ... & Hoefnagel, M. H. (2023). Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines. *Vaccine*, 41(38), 5603-5613.
- Zhou, G., **Verweij, S.**, Bijlsma, M. J., de Vos, S., Rengerink, K. O., Pasmooij, A. M. G., ... & Hak, E. (2023). Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis. *BMJ open respiratory research*, 10(1), e001674.
- de Vries, S. T., Al-Mugoter, N. H. S., Petkoska, I., **Verweij, S.**, Elferink, A. J., &

Mol, P. G. (2024). Comment on:“The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”. *Applied Health Economics and Health Policy*, 22(1), 123-124.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)